CN104055817A - Composition with sedative effect and atomization preparation thereof - Google Patents
Composition with sedative effect and atomization preparation thereof Download PDFInfo
- Publication number
- CN104055817A CN104055817A CN201310088066.6A CN201310088066A CN104055817A CN 104055817 A CN104055817 A CN 104055817A CN 201310088066 A CN201310088066 A CN 201310088066A CN 104055817 A CN104055817 A CN 104055817A
- Authority
- CN
- China
- Prior art keywords
- compositions
- oil
- chamomile
- tea polyphenols
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000000889 atomisation Methods 0.000 title claims abstract description 11
- 230000001624 sedative effect Effects 0.000 title abstract 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims abstract description 61
- 244000042664 Matricaria chamomilla Species 0.000 claims abstract description 61
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 61
- 230000000694 effects Effects 0.000 claims abstract description 60
- 239000000341 volatile oil Substances 0.000 claims abstract description 52
- 244000269722 Thea sinensis Species 0.000 claims abstract description 48
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 42
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 42
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 38
- 244000178870 Lavandula angustifolia Species 0.000 claims abstract description 24
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims abstract description 24
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 19
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000011709 vitamin E Substances 0.000 claims abstract description 19
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 19
- 229940046009 vitamin E Drugs 0.000 claims abstract description 19
- 239000003921 oil Substances 0.000 claims description 62
- 235000013616 tea Nutrition 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 235000009569 green tea Nutrition 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 8
- 238000013517 stratification Methods 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 208000007443 Neurasthenia Diseases 0.000 abstract description 13
- 206010003549 asthenia Diseases 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 9
- 235000018219 lavender Nutrition 0.000 abstract description 6
- 239000001102 lavandula vera Substances 0.000 abstract description 2
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- 239000000932 sedative agent Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 239000003380 propellant Substances 0.000 description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 244000251953 Agaricus brunnescens Species 0.000 description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 229960002275 pentobarbital sodium Drugs 0.000 description 7
- 230000002567 autonomic effect Effects 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000723353 Chrysanthemum Species 0.000 description 5
- 235000007516 Chrysanthemum Nutrition 0.000 description 5
- 230000001914 calming effect Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000004620 sleep latency Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000001256 steam distillation Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 244000166124 Eucalyptus globulus Species 0.000 description 2
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- CZVXBFUKBZRMKR-UHFFFAOYSA-N lavandulol Chemical compound CC(C)=CCC(CO)C(C)=C CZVXBFUKBZRMKR-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CZVXBFUKBZRMKR-JTQLQIEISA-N (R)-lavandulol Natural products CC(C)=CC[C@@H](CO)C(C)=C CZVXBFUKBZRMKR-JTQLQIEISA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- 241000722824 Ardisia crenata Species 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241001473471 Conoclinium coelestinum Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241001473317 Eupatorium cannabinum Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000827798 Hemerocallis citrina Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003571 electronic cigarette Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- -1 health care Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000002475 olfactory pathway Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Abstract
The invention provides a composition with a sedative effect and an atomization preparation thereof. The composition comprises chamomile volatile oil or lavender volatile oil, tea polyphenol and vitamin E, has sedative and tranquillizing effects, no toxic and side effects and good stability, is easy to absorb by a human body and can effectively inhibit symptoms like neurasthenia.
Description
Technical field
The present invention relates to field of medicaments, especially relate to a kind of atomization preparation of compositions and the use said composition with calm effect.
Background technology
Modern social economy high speed development, urbanization rhythm and process of industrialization are accelerated, people's rhythm of life is also constantly accelerated and pressure is also increasing, and increasing people occurs anxiety, worry, is entangled with, insomnia, psychentonia, depression, the neurasthenia symptom such as manic.According to incompletely statistics, in developing country, neurasthenic sickness rate accounts for the more than 10% of normal population, and in developed country, up to 20%, neurasthenia has had a strong impact on people's quality of life.
Neurasthenia can directly cause the infringement of the multiple systems of human body, and causes the diseases such as hypertension, arrhythmia, cerebrovascular disease, diabetes and nephropathy.At present, clinical medicine is applied class medicine as stable in alprazolam, triazolam, clonazepam, estazolam, midazolam etc. mostly as suppressing as the treatment means of the neurasthenias such as insomnia.These medicines just can take effect in a short time, but human body has obvious dependency for this class medicine, just make the symptoms such as insomnia serious all the more once stop using; And this class medicine has larger side effect, the ill symptoms such as that long-term taking can cause is poisoning, bring out maniac access, orgasm goes down, it is impaired that more severe patient directly causes central nervous system, makes patient occur headache, drowsiness, dizzy, the lower degradation situation of memory; For anemia of pregnant woman, can cause fetal anomaly to have cleft palate, chapped lip or inguinal hernia.Neurasthenia's stubbornness and refractory, just be called as " not dead cancer " as insomnia.In view of limitation and the untoward reaction of Western medicine in treatment neurasthenia use, utilize natural Chinese medicinal herb to develop the important directions that the little neurasthenia medicine of new side effect is the research of current this area.For example, Chinese patent application document CN1569059A discloses the technical scheme of a kind of use taking the extract of Eupatorium cannabinum L. (Eupatorium coelestinum L.) as the oral formulations treatment of insomnia patients of main component.
In the above-mentioned research that utilizes Chinese herbal medicine, from natural plants, extract plants essential oil, being mixed with compound medicine is a focus of studying at present with treatment neurasthenia.So-called plants essential oil refers to the volatile flavor that refines extraction from flower, leaf, stem, root or the fruit of plant.Plants essential oil, containing chemical compositions such as artificial essence, artificial color, synthetic preservative, mineral greases, is not considered to be difficult for causing human allergy etc. conventionally.In plants essential oil, Herba Lysimachiae foenum-graeci quintessence oil and Hemerocallis citrina Baroni chrysanthemum quintessence oil are loved by the people because of their good pharmacological effect and having no side effect.
Lavandula angustifolia (Lavender), its leaf, stem, flower Herb are giving off a strong fragrance, and aromatic flavor and soft, has no side effect at stingless excitation, is precious Chinese crude drug and food flavor.In lavandula angustifolia, essential oil content is higher, and smart main body of oil is the compounds such as linalool, linalyl acetate, acetic acid lavandula angustifolia ester and lavandulol.Pharmacological research shows, Herba Lysimachiae foenum-graeci quintessence oil has the effects such as relaxing smooth muscle, convulsion, calmness, antidepressant, can replace sleeping pill, can also promote cell regeneration, balance sebum secretion, repair calcination and sunburn, infection; Its fragrance energy appetite stimulator strengthens healthy, and has antioxidative usefulness, is widely used in medicine, health care, cosmetic, washing, food service industry.For example, Chinese patent application document CN102416109A discloses a kind of compound essential-oil sleep-helpful capsule that comprises the components such as Herba Lysimachiae foenum-graeci quintessence oil, Oleum Vitis viniferae, vitamin E, propolis, vitamin B1, Semen Tritici aestivi germ oil, dextrin, and it has effect of calming soporific.Chinese patent application document CN10163276A discloses a kind of essential oil of traditional Chinese medicine with the effect of calming the nerves that comprises Rhizoma Acori Graminei extract, Fructus Anisi Stellati extract, Herba Schizonepetae extract Folium eucalypti globueli (Eucalyptus globulus Labill.) extract, Folium cinnamomi camphorae extract, lavandula angustifolia Oleum sesami, Herba Menthae wet goods component.
Chamomile (Chamomile), it contains volatile aromatic oil, is a kind of important medicinal plants and spice berry.Chamomile volatile oil, is popular health care and pharmaceutical preparation, has calmness, loosens, helps effect of sleep, can alleviate anxiety, anxiety, indignation and fear; People is loosened patience, happy and auspicious, allows soul calmness; And Chamomile has stronger anti-inflammatory activity, can alleviate patient's the symptom such as inflammation, pain and the insomnia being caused by nerve skin pruritus; Chamomile also has the effect of antiinflammatory and Antifungi simultaneously.Chamomile volatile oil has unique fragrance concurrently; in Europe; Chamomile is often made into teabag; for Cure for insomnia, laryngitis, sciatica, dyspepsia or be applied to cosmetics as in lip pomade, medicated soap, suntan lotion, shampoo; fragrance can be produced and skin cracking, inflammation can be prevented again; play a protective role, allocate into and in collutory, can effectively treat toothache.In addition, Chamomile volatile oil has fragrant as natural rose and can be used as the flavoring agent of food, beverage and sweet wine.
But natural plant volatile oil volatility is large, stability and absorption of human body are poor, even if make the forms such as capsule, are still difficult to be absorbed by human body.As pharmaceutical, it is not remarkable for the neurasthenic curative effect for the treatment of now.Thereby, how to improve the stability of plant volatile oil, and make it better for absorption of human body, improve treatment neurasthenia symptom curative effect, be significant for treatment neurasthenia symptom at medical domain.
Summary of the invention
The invention provides a kind of compositions with calm effect and atomization preparation thereof having no side effect.Described compositions includes spring flower chrysanthemum volatile oil or lavenderessential oil and tea polyphenols and pharmaceutical excipient.Described composition stable is strong, is easily absorbed by the body, and can effectively suppress the symptoms such as neurasthenia.
Alternatively, described excipient is diluent.
Alternatively, described diluent is propylene glycol.
Alternatively, described compositions also comprises that vitamin E is using as stabilizing agent, alleviates the oxidation of Chamomile volatile oil or lavenderessential oil, tea polyphenols.
Alternatively, described compositions is containing Chamomile volatile oil or the lavenderessential oil of 0.01～1 % by weight, and the vitamin E of the tea polyphenols of 0.01～10 % by weight and 0～2 % by weight.
Alternatively, described compositions is containing Chamomile volatile oil or the lavenderessential oil of 0.03～0.8 % by weight.And the tea polyphenols of 0.01～5 % by weight, and the vitamin E of 0.5～1.5 % by weight.
Alternatively, described compositions is containing Chamomile volatile oil or the lavenderessential oil of 0.4～0.7 % by weight, and the vitamin E of the tea polyphenols of 0.2～0.8 % by weight and 0.8～1.5 % by weight.
Alternatively, described Chamomile volatile oil or lavenderessential oil are the water distillation and extraction thing of Chamomile dry flower or lavandula angustifolia dry flower,
Described spring flower chrysanthemum volatile oil or lavenderessential oil obtain with following methods:
After Chamomile dry flower or lavandula angustifolia dry flower are pulverized, be soaked in water 2.5～4 hours; Then use vapor distillation 2～4 hours, by cooling distillate and stratification, obtain extracting Chamomile dry flower or lavenderessential oil, and dry.
Alternatively, after described Chamomile dry flower or lavandula angustifolia dry flower are pulverized, cross 40 mesh sieves, obtain dry flower powder, the solid-liquid ratio of described dry flower powder and water is 1:16～24.
Alternatively, described tea polyphenols is by distilling under reduced pressure after extracting by aqueous alcohol solutions after will green tea pulverizing, then obtains with chloroform extraction.
Alternatively, the method for obtaining tea polyphenols from green tea is:
Alcohol reflux secondary by green tea powder with 60～80vol%, merge extractive liquid,, ethanol is heated up in a steamer in decompression;
After filtration or centrifugal removing after impurity, further concentrated described extracting solution;
By after described extracting solution and chloroform mix and blend, stratification, obtains upper water solution afterwards;
Upper water solution described in lyophilization, obtains tea polyphenols powder.
The present invention also provides a kind of atomization preparation, and it comprises the above-mentioned compositions with calm effect.
Compared with prior art, the present invention has the following advantages:
Measure through mouse experiment, Chamomile volatile oil or the lavenderessential oil of containing of the present invention, and the compositions with calm effect of vitamin E and tea polyphenols is than the comparison example that only contains Chamomile volatile oil or lavenderessential oil and vitamin E, identical in the situation that, the compositions with calm effect provided by the invention can obviously shorten the Sleep latency of mice, extend the length of one's sleep, improve mice sleep quality; Can reduce the movable number of times of mice, stablize well mice emotion simultaneously.From above experiment,
The present invention has calmness, the effect of calming the nerves, and effectively suppresses mice neurasthenia symptom.
In addition, the atomization preparation that contains the compositions with calm effect of the present invention is conducive to the absorption of human body for the compositions of calm effect, thereby improves compositions calmness, the effect of calming the nerves.
Detailed description of the invention
The compositions with calm effect provided by the present invention, taking Chamomile volatile oil or lavenderessential oil and tea polyphenols and pharmaceutical excipient as main component.Wherein, described excipient is preferably diluent, is selected from alcohols, as ethanol, ethylene glycol, normal propyl alcohol, n-butyl alcohol etc.Wherein, preferred propylene glycol is as diluent.
The Chamomile volatile oil that can use in the present invention and the lavenderessential oil distillation for obtaining with hydrodistillation.Its method is as follows:
Step 1: after Chamomile dry flower or lavandula angustifolia dry flower are pulverized, be soaked in appropriate water 2.5～4 hours;
Step 2: by above-mentioned soak ebuillition of heated 2～3 hours, and distillation is cooling, obtain fraction; Leave standstill fraction, make its layering, extract the oil reservoir on upper strata;
Step 3: add dried over anhydrous sodium carbonate in the oil reservoir extracting, obtain after filtering Chamomile dry flower or lavenderessential oil.
Wherein, after described Chamomile dry flower or the pulverizing of lavandula angustifolia dry flower, the powder obtaining after pulverizing is crossed to 40 mesh sieves, obtain Chamomile dry flower or lavandula angustifolia dry flower powder that granule is less, be immersed in again afterwards in water, be easy to like this Chamomile volatile oil or lavenderessential oil and extract.And Chamomile dry flower powder or lavandula angustifolia dry flower powder with the solid-liquid ratio for the water that soaks for being preferably 1:16～24.If the content of water is too small, the extraction of Chamomile volatile oil or lavenderessential oil is abundant not; Cross that depleting substance is excessive at most, and the also corresponding raising of energy consumption of distillation operation afterwards, waste caused.Soak time is determined according to concrete material ratio.Wherein, more preferably 1:20 left and right of described solid-liquid ratio.
It should be noted that, the spring flower chrysanthemum place of production comprises European all states such as Germany, Britain, Morocco, Hungary, Russia, Yugoslavia, also cultivate in a large number in Xinjiang, China Yi Li and other places, in the Chamomile in the different places of production, extract spring flower chrysanthemum volatile oil component slightly different, it is applied to also difference slightly of calm effect after the compositions that the present invention has calm effect, realizes but these nuances do not affect the object of the invention.Equally, lavenderessential oil is also like this.
The Chamomile volatile oil that can use in the present invention and lavenderessential oil are except employing said method obtains, also can use Chamomile volatile oil and lavenderessential oil on sale on market, as the supercritical Chamomile quintessence oil of Xi'an rising sun Science and Technology Ltd., the Herba Lysimachiae foenum-graeci quintessence oil of lavandula angustifolia technological development company limited of Shenzhen.They can use in the present invention substantially on an equal basis effectively.
The tea polyphenols using in the present invention is for extracting by aqueous alcohol solutions after green tea is pulverized, and the product obtaining with chloroform extraction.Its detailed process comprises:
Step 1: the alcohol reflux secondary by green tea powder with 60～80vol%, merge extractive liquid,, ethanol is heated up in a steamer in decompression, obtains extracting solution.
Wherein, secondary alcohol reflux process can be, and first in green tea powder, adds the ethanol of the 70vol% left and right of 7～9 times of volumes, refluxes about 2 hours; For the second time with the same purity alcohol reflux of 6～8 times of volumes about 1 hour, and merge the extracting solution that twice backflow obtained;
By the extracting liquid filtering being obtained by above-mentioned twice alcohol reflux, the filtrate of obtaining is heated up in a steamer ethanol through decompression, obtains extracting solution afterwards.
Step 2: by said extracted liquid after filtration or rotary process, to remove after the insoluble matter impurity in extracting solution, filtrate is carried out to enrichment process, slough part water.
Step 3: the extracting solution obtaining in step 2 is mixed with the volume ratio of 3:2 left and right with chloroform, and after fully stirring, leave standstill, to mixed solution layering, obtain upper water solution.Adopt through flat plate ultrafiltration equipment the upper water solution obtaining is carried out to clarifying treatment afterwards, obtain settled solution.
Step 4: the settled solution obtaining is carried out to lyophilization processing, obtain tea polyphenols powder.
The tea polyphenols that can use in the present invention, except available said method prepares, also can use product on sale on market, as Anhui Red Star Pharmaceutical Co., Ltd, the tea polyphenols of 50%EGCG.Also can be the tea polyphenols obtaining by supercritical carbon dioxide extraction method.They can use in the present invention substantially on an equal basis effectively.
Preferably, the compositions with calm effect of the present invention also comprises vitamin E.Wherein, described in, there is Chamomile volatile oil or the lavenderessential oil that the compositions of calm effect comprises 0.01～1 % by weight, and the vitamin E % of the tea polyphenols of 0.01～10 % by weight and 0～2 % by weight.Preferably, Chamomile volatile oil or lavenderessential oil that described compositions comprises 0.03～0.8 % by weight, and the vitamin E of the tea polyphenols of 0.01～5 % by weight and 0.5～1.5 % by weight.More preferably, Chamomile volatile oil or lavenderessential oil that described compositions contains 0.4～0.7 % by weight, and the vitamin E of the tea polyphenols of 0.2～0.8 % by weight and 0.8～1.5 % by weight.
The present invention has in the compositions of calm effect, Chamomile volatile oil or lavenderessential oil have calm effect, tea polyphenols has efficiently calms, suppresses the irritated emotion of people to suppress the neurasthenic effect of people, by Chamomile volatile oil or lavenderessential oil and tea polyphenols merging, and add certain vitamin E with antioxidation, again with mixing diluents after, increased effect useful to human body than single in the past with Chamomile volatile oil or lavenderessential oil and diluent.And tea polyphenols and vitamin E both have antioxidation, there is the function of Synergistic, not only protect better the stability of volatile oil, also improve compositions effect simultaneously.
Wherein, the compositions that the present invention has calm effect also can comprise as Rhizoma Acori Graminei extract, Herba Schizonepetae extract Folium eucalypti globueli (Eucalyptus globulus Labill.) extract, Herba Menthae wet goods Chinese medicine ingredients, and if the compositions such as vitamin B1 are to strengthen effect of the present invention.
The compositions that the present invention has calm effect can be made into various pharmaceutical dosage forms such as being applicable to oral administration, intravenous administration, sublingual administration.Use with forms such as solid, solution, emulsion, dispersion, micelle, liposomees.Particularly can type of service comprise tablet, granule, pill, capsule, buccal tablet, aqueous suspension or oil suspending agent, tincture, dispersible powder, solution, Emulsion, suspending agent and other suitable forms.Wherein, particularly preferably the invention provides a kind of atomization preparation that comprises the above-mentioned compositions with calm effect.It can mix the Chamomile volatile oil that contains aforementioned proportion or lavenderessential oil, tea polyphenols, vitamin E, makes compound recipe atomization preparation, and adopts medical atomized equipment and electronic cigarette to make propellant form to use.
Above-mentioned when comprising the above-mentioned compositions with calm effect and using with the form of propellant, human body, by atomization absorption, directly absorbs the effective ingredient of Chamomile or Garden lavender to enter blood, and easier compositions is brought into play its effect.Particularly, propellant sucks after nasal cavity, passes to the olfactory epithelium of nasal cavity upper back by nasal meatus, be passed to again olfactory bulb, be delivered to olfactory cortex, then send instruction via brain nervus centralis, remove regulation and control and balance autonomic nervous system, thereby generation is calmed, is loosened, joyful or excited effect.Thereby propellant that human body is absorbed for the compositions effective ingredient of calm effect is more abundant, and these effective ingredient are faster action time in human body, thus better performance calmness, the nerve that loosens, releives, ease off the pressure, the effect such as hypnotic.Simultaneously, tea polyphenols is a kind of natural polyphenol class material extracting from Folium Camelliae sinensis, there is the ability of good antioxidation and removing free radical, also suck pulmonary by propellant, enter blood circulation in pulmonary, play removing free radical, reduce body inner lipid peroxidating degree, pre-anti-aging effect.Chamomile volatile oil or Garden lavender volatile oil have unique fragrance concurrently, are more easily accepted by consumer.
In addition, the use procedure of propellant shape is convenient, without dilution, preparation, greatly reduces the possible microbial contamination in use procedure, makes propellant product provided by the invention use safer, health, convenience.
We further describe the present invention by specific embodiment and experiment below, and still, following embodiment is only example of the present invention, and should not think limiting the scope of the invention.
Embodiment 1
Tea polyphenols preparation:
Get commercially available Longjing green tea Folium Camelliae sinensis 5kg, use pulverizer coarse pulverization.With containing twice of the aqueous solution reflux, extract, of 70vol% ethanol, add the ethanol-water solution that is equivalent to 8 times of volumes of green tea the 1st time, reflux 2 hours, the ethanol-water solution of 7 times of volumes of the 2nd use, reflux 1 hour, merge the above-mentioned extracting solution that adds for twice ethanol-water solution to reflux and to obtain.After to extracting liquid filtering, by filtrate decompression distillation, reclaim ethanol, collect extracting solution;
Said extracted liquid is removed after insoluble matter after filtration, and concentrated described extracting solution, removes part water, for next procedure.Afterwards, chloroform and extracting solution are mixed according to volume ratio 3:2, after abundant stirring stratification, get upper water solution;
Upper water solution is carried out to clarifying treatment with flat plate ultrafiltration equipment, obtain clear liquor; By clear liquor lyophilization, obtain tea polyphenol powder 540g.
The preparation of Chamomile volatile oil:
Take Chamomile dry flower and (originate in Xuancheng Profile, anhui Province.Air-dry through 1 week under the room temperature of approximately 25 DEG C) 5kg, pulverizer is pulverized, and crosses 40 mesh sieves, adds 100L water soaking 3 hours.With steam distillation 3 hours, collect distillate, through stratification, collect upper strata oil reservoir;
In oil reservoir, add anhydrous sodium sulfate drying, obtain dry Chamomile volatile oil 42g.
Above-mentioned Chamomile volatile oil 0.5 weight portion making, tea polyphenols 0.5 weight portion are mixed with vitamin e1 .0 weight portion and propylene glycol 98 weight portions, make propellant 1(formula 1).
Embodiment 2
Lavenderessential oil preparation:
Take lavandula angustifolia dry flower and (originate in Xinjiang Yili of China.Air-dry through 1 week under the room temperature of approximately 25 DEG C) 5kg, pulverizer is pulverized, and crosses 40 mesh sieves, adds 80L water soaking 3 hours.With steam distillation 3.5 hours, collect distillate, through stratification, collect upper strata oil reservoir.
In oil reservoir, add anhydrous sodium sulfate drying, obtain dry lavenderessential oil 45g.
Tea polyphenols 0.5 weight portion making in above-mentioned Garden lavender volatile oil 0.5 weight portion making, embodiment 1 is mixed with vitamin e1 .0 weight portion and propylene glycol 98 weight portions, make propellant 2(formula 2).
Embodiment 3
Lavenderessential oil preparation:
Take lavandula angustifolia dry flower and (originate in Xinjiang Yili of China.Air-dry through 1 week under the room temperature of approximately 25 DEG C) 5kg, pulverizer is pulverized, and crosses 40 mesh sieves, adds 100L water soaking 3 hours.With steam distillation 3 hours, collect distillate, through stratification, collect upper strata oil reservoir;
In oil reservoir, add anhydrous sodium sulfate drying, obtain dry lavenderessential oil 41g.
Tea polyphenols 10 weight portions that make in above-mentioned Garden lavender volatile oil 1.0 weight portions that make, embodiment 1 are mixed with vitamin e1 .0 weight portion and propylene glycol 88 weight portions, make propellant 3.
Carry out pharmacological evaluation with the propellant obtaining in embodiment 1 and embodiment 2.
Pharmacological experimental example 1
1. reagent and instrument:
Fumigation device: self-control 80cm × 40cm × 36cm wooden case.Wherein, centre is divided into two halves with wire gauze, places Fragrance Lamp (production of Guangzhou Ao Te Electronic Science and Technology Co., Ltd.) on one side, is used for placing mice on one side, leaves passage at the side lower part of wooden case, and glass sliding door is established at top so that operation and observation.
Gauge: YLS-1A Multifunctional mouse autonomic activities monitor (Jinan Yi Yan development in science and technology company limited, former Shandong Academy of Medical Sciences's equipment station produces).
Tranquilizer: pentobarbital sodium;
Propellant: formula 1 does not contain tea polyphenols for the propellant 1 of embodiment 1, propellant 2 that formula 2 is embodiment 2, formula 3 as a comparison case and formula 4 are respectively, only contain respectively the Chamomile volatile oil that makes in embodiment 1 and 2 and the propellant of lavenderessential oil, formula 5 be not containing any propellant (specifically formula components is as shown in table 1) in Chamomile volatile oil and lavenderessential oil.
The propellant of table 1.5 kind of different formulations
Animal: SFF (SPF) level KM male mice (body weight 22～26g).
2. experimental technique:
2.1. to mice pentobarbital sodium induced hypnotic time and experiment incubation period, its specific operation process is:
Divide 6 groups at random by mice, propellant (as formula 1 and the formula 2 of embodiment, formula 3, formula 4 and formula 5 as a comparison case) is organized and matched group (not implementing incense) 10 every group.Matched group gives the pentobarbital sodium solution lumbar injection of 50mg/kg; Champignon group according to after 5 kinds of Formulation Implementation champignon 30min, gives the pentobarbital sodium solution lumbar injection of 50mg/kg respectively immediately.
Observe and record dropping asleep latency (sleeping duration) and the length of one's sleep (righting reflex loss is to the time of recovering) of mice.
2.2. the impact on mice autonomic activities
By points 6 groups at random of mices, propellant (formula 1, formula 2, formula 3, formula 4, formula 5) group and matched group (not implementing incense), 10 every group.Control group mice is not implemented champignon, and champignon group mice is respectively according to after 5 kinds of Formulation Implementation champignon 30min.Mice is put into YLS-1A Multifunctional mouse autonomic activities monitor, record mice autonomic activities number of times in 10min.
All experimental datas are used
represent, adopt one factor analysis of variance, P < 0.05 has statistical significance for difference.
3. experimental result
3.1 is as shown in table 2 on the experimental data of mice pentobarbital sodium induced hypnotic time and preclinical impact.
The comparison length of one's sleep of the each group of table 2. mice threshold dose pentobarbital sodium
As shown in table 2: in the sleep test of threshold dose pentobarbital sodium induction, compared with matched group, as the mice in 4 groups of 1 group of the formula of embodiment, 2 groups of formulas and 3 groups of formulas as a comparison case, formulas after propellant champignon, Sleep latency all shortens, all extend the length of one's sleep, and difference has statistical significance (P < 0.05).Be compared to 3 groups of mices of formula of comparative example as 1 group of the formula of embodiment simultaneously, the Sleep latency of mice that is compared to 4 groups of the formulas of comparative example as 2 groups of the formulas of embodiment is shorter, more extend the length of one's sleep, significant difference (P < 0.05).Mice in 5 groups of formulas is as a comparison case after propellant champignon, and its Sleep latency was compared with the length of one's sleep with the Sleep latency of the mice in matched group with the length of one's sleep, no significant difference.
The experimental data of 3.2 impacts on mice autonomic activities is as shown in table 3.
The comparison of the each group of table 3. times of exercise
As shown in table 3: be used as after the propellant champignon of 4 groups of 1 group of formula, 2 groups of formulas and 3 groups of formulas as a comparison case, formulas of embodiment, the times of exercise of mice is obviously less than matched group (P < 0.05).And, be compared to the formula 3 of comparative example as the formula 1 of embodiment, be compared to the formula 4 of comparative example as the formula 2 of embodiment, with after propellant champignon, the times of exercise of mice reduces more.But be used as after the propellant champignon of formula 5 of comparative example, the autonomic activities of mice is had no significant effect.
The above results shows, the propellant that contains Herba Lysimachiae foenum-graeci quintessence oil and the propellant that contains Chamomile quintessence oil have sedative-hypnotic effect, but after interpolation tea polyphenols, its calmness, the successful of calming the nerves improve, obviously exceed the effect of independent use Herba Lysimachiae foenum-graeci quintessence oil or Chamomile quintessence oil, even exceed the effect of independent use Herba Lysimachiae foenum-graeci quintessence oil or Chamomile quintessence oil and the simple superposition sum of the effect of use tea polyphenols, show that Herba Lysimachiae foenum-graeci quintessence oil and Chamomile quintessence oil and tea polyphenols have synergistic function.Its mechanism still do not understand, but infers it may is the activity that antioxidation, effect of scavenging radical that tea polyphenols has have improved cell, thereby produced the effect of Synergistic with the sedation of the quintessence oil of lavandula angustifolia and Chamomile.It should be noted that; in the various embodiments described above, all add vitamin E; it is not oxidized that it can effectively protect the present invention to have in the compositions of calm effect effective ingredient (comprising Chamomile volatile oil, lavenderessential oil, tea polyphenols), improves the present invention and have the stable effect of the compositions of calm effect.
Above-mentioned specific embodiment is just in order to make those skilled in the art understand better essence of the present invention; but; protection scope of the present invention is not limited with the specific descriptions of these specific embodiments; not departing from the scope of essence of the present invention; those skilled in the art can modify and change the specific embodiment of the present invention, and these modifications and changes still belong to protection scope of the present invention.
Claims (10)
1. a compositions with calm effect, is characterized in that, comprising: Chamomile volatile oil or lavenderessential oil, and tea polyphenols and pharmaceutical excipient.
2. the compositions with calm effect as claimed in claim 1, is characterized in that, described pharmaceutical excipient is diluent.
3. the compositions with calm effect as claimed in claim 1, is characterized in that, described compositions also comprises vitamin E.
4. the compositions with calm effect as described in claim 1 or 3, is characterized in that, the tea polyphenols of the Chamomile volatile oil that described compositions contains 0.01～1 % by weight or lavenderessential oil and 0.01～10 % by weight and the vitamin E of 0～2 % by weight.
5. the compositions with calm effect as claimed in claim 4, it is characterized in that the tea polyphenols of the Chamomile volatile oil that described compositions contains 0.4～0.7 % by weight or lavenderessential oil and 0.2～0.8 % by weight and the vitamin E of 0.8～1.5 % by weight.
6. the compositions with calm effect as claimed in claim 1, is characterized in that, described Chamomile volatile oil or lavenderessential oil are the water distillation and extraction thing of Chamomile dry flower or lavandula angustifolia dry flower,
Obtain by the following method:
After Chamomile dry flower or lavandula angustifolia dry flower are pulverized, be soaked in water 2.5～4 hours, then use vapor distillation 2～4 hours, cooling distillate and stratification is obtained.
7. the compositions with calm effect as claimed in claim 6, is characterized in that, after described Chamomile dry flower or lavandula angustifolia dry flower are pulverized, crosses 40 mesh sieves;
The solid-liquid ratio of dry flower powder and water is 1:16～24.
8. the compositions with calm effect as claimed in claim 1, is characterized in that, described tea polyphenols is by distilling under reduced pressure after extracting by aqueous alcohol solutions after will green tea pulverizing, then obtains with chloroform extraction.
9. the compositions with calm effect as claimed in claim 8, is characterized in that, described tea polyphenols obtains with following methods:
Alcohol reflux secondary by green tea powder with 60～80vol%, merge extractive liquid,, ethanol is heated up in a steamer in decompression;
After filtration or centrifugal removing after impurity, further concentrated described extracting solution;
By after described extracting solution and chloroform mix and blend, stratification, obtains upper water solution;
Upper water solution described in lyophilization, obtains tea polyphenols powder.
10. an atomization preparation, is characterized in that, comprises the compositions with calm effect described in any one in claim 1～9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310088066.6A CN104055817B8 (en) | 2013-03-19 | 2013-03-19 | It is a kind of to have effects that calm composition and its atomization preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310088066.6A CN104055817B8 (en) | 2013-03-19 | 2013-03-19 | It is a kind of to have effects that calm composition and its atomization preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| CN104055817A true CN104055817A (en) | 2014-09-24 |
| CN104055817B CN104055817B (en) | 2017-07-21 |
| CN104055817B8 CN104055817B8 (en) | 2018-08-07 |
Family
ID=51543936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310088066.6A Active CN104055817B8 (en) | 2013-03-19 | 2013-03-19 | It is a kind of to have effects that calm composition and its atomization preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104055817B8 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104770864A (en) * | 2015-02-13 | 2015-07-15 | 华健 | Heat-clearing and throat-wetting electronic spray solution and preparation method thereof |
| CN107812107A (en) * | 2017-11-09 | 2018-03-20 | 上海羿康生物科技有限公司 | A kind of atomization preparation containing anti-oxidation function plant extracts of refreshing oneself and its preparation method and application |
| CN110151868A (en) * | 2019-05-28 | 2019-08-23 | 厦门梓素生物科技有限公司 | A kind of essential oil and preparation method thereof of the extract of CBD containing cannabidiol |
| CN113350557A (en) * | 2020-03-06 | 2021-09-07 | 李彤 | Multipurpose aromatherapy liquid |
| CN113384781A (en) * | 2020-03-11 | 2021-09-14 | 李彤 | EGCG atomization system |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632761A (en) * | 2008-11-22 | 2010-01-27 | 中山市中南烛业有限公司 | Nerves-soothing compound oil, essential oil of traditional Chinese medicine and aromatherapy products having nerves-soothing function |
| CN101829240A (en) * | 2010-05-17 | 2010-09-15 | 上海鼎利生物科技有限公司 | Atomizing preparation containing plant extract and preparation method thereof |
| CN102416109A (en) * | 2011-11-18 | 2012-04-18 | 大连得达科技发展有限公司 | Compound essential-oil sleep-helpful capsule |
-
2013
- 2013-03-19 CN CN201310088066.6A patent/CN104055817B8/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632761A (en) * | 2008-11-22 | 2010-01-27 | 中山市中南烛业有限公司 | Nerves-soothing compound oil, essential oil of traditional Chinese medicine and aromatherapy products having nerves-soothing function |
| CN101829240A (en) * | 2010-05-17 | 2010-09-15 | 上海鼎利生物科技有限公司 | Atomizing preparation containing plant extract and preparation method thereof |
| CN102416109A (en) * | 2011-11-18 | 2012-04-18 | 大连得达科技发展有限公司 | Compound essential-oil sleep-helpful capsule |
Non-Patent Citations (3)
| Title |
|---|
| 八卷英彦等: "芳香治疗法的药理效用", 《香料与香精》 * |
| 朴多荣: "《3元自制好口碑天然面膜》", 31 July 2010, 中国轻工业出版社 * |
| 梅家齐: "芳香吸入疗法的应用原理", 《香料香精化妆品》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104770864A (en) * | 2015-02-13 | 2015-07-15 | 华健 | Heat-clearing and throat-wetting electronic spray solution and preparation method thereof |
| CN107812107A (en) * | 2017-11-09 | 2018-03-20 | 上海羿康生物科技有限公司 | A kind of atomization preparation containing anti-oxidation function plant extracts of refreshing oneself and its preparation method and application |
| CN110151868A (en) * | 2019-05-28 | 2019-08-23 | 厦门梓素生物科技有限公司 | A kind of essential oil and preparation method thereof of the extract of CBD containing cannabidiol |
| CN113350557A (en) * | 2020-03-06 | 2021-09-07 | 李彤 | Multipurpose aromatherapy liquid |
| CN113384781A (en) * | 2020-03-11 | 2021-09-14 | 李彤 | EGCG atomization system |
| CN113384781B (en) * | 2020-03-11 | 2024-03-29 | 李彤 | EGCG atomizing system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104055817B8 (en) | 2018-08-07 |
| CN104055817B (en) | 2017-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614102B (en) | Dandruff-removing medicinal composition and preparation method thereof | |
| CN106214592B (en) | Hair follicle nutrient liquor composition and preparation method thereof | |
| CN104940050A (en) | Use of agilawood volatile oil stoste in preparation of skin-care product | |
| CN102697830B (en) | Pharmaceutical composition for preventing and treating menstrual disease and preparation method and application of composition | |
| CN104055817A (en) | Composition with sedative effect and atomization preparation thereof | |
| CN103830440A (en) | Health care essential oil with sedative effect | |
| CN102727658B (en) | Chinese herbal extract with anti-dropping and oil-controlling effects, preparation method and application thereof | |
| KR20170130213A (en) | A composition for preventing hair loss and promoting hair growth comprising medical herbs, and manufacturing method thereof | |
| CN103655890A (en) | Compound liniment for preventing and treating alopecia areata | |
| CN105232824A (en) | Tea oil composition and preparing method and application thereof | |
| CN104288815A (en) | Traditional Chinese medicine incense and preparation method thereof | |
| CN107854681A (en) | A kind of anti-inflammatory composition and preparation method thereof | |
| CN105213541B (en) | Improve the Rose compound essential oil and preparation method thereof of insomnia due to pressure | |
| CN103735443A (en) | Alopecia-resistant smoothing shampoo and preparation method thereof | |
| CN106265938A (en) | A kind of Chinese crude drug bathing agent and preparation method thereof | |
| CN106420582A (en) | Preparation method for traditional Chinese medicinal lip balm | |
| CN103341044B (en) | Itching-relieving compound preparation and preparation method thereof | |
| CN105920379A (en) | Traditional Chinese medicine eye cream to alleviate pouch and preparation method thereof | |
| CN105919907A (en) | Manufacturing method of traditional Chinese medicine eye cream and eye cream | |
| CN112076268A (en) | Traditional Chinese medicine lotion for preventing and treating alopecia and blackening hair, preparation method and application | |
| CN105434264A (en) | Motherwort-herb toothpaste | |
| CN101647900B (en) | Traditional Chinese medicine preparation capable of improving sleep and relaxing the bowel to relieve constipation and preparation method thereof | |
| CN105125436B (en) | A kind of composite whitening composition and preparation method | |
| CN104940524B (en) | It is a kind of to be used to treat drug of leucoderma and preparation method thereof | |
| CN109260255A (en) | A kind of woody compound sunstroke prevention essential oil and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI YIKANG BIO-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HUZHOU DINGKANG BIOTECHNOLOGY CO., LTD. Effective date: 20150724 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150724 Address after: 200233, room 418, 507 Guiping Road, Shanghai, Xuhui District Applicant after: Shanghai Yikang Biotechnology Co.,Ltd. Address before: 313028 building, building 2, building 3, Wuxing science and technology innovation garden, eight Li Town, Huzhou, Zhejiang Applicant before: HUZHOU DINGKANG BIOTECHNOLOGY CO.,LTD. |
|
| GR01 | Patent grant | ||
| CI03 | Correction of invention patent | ||
| CI03 | Correction of invention patent |
Correction item: Patentee Correct: SHANGHAI YIKANG BIOLOGICAL TECHNOLOGY Co.,Ltd. False: Shanghai Yikang Biotechnology Co.,Ltd. Number: 29-02 Page: The title page Volume: 33 Correction item: Patentee Correct: SHANGHAI YIKANG BIOLOGICAL TECHNOLOGY Co.,Ltd. False: Shanghai Yikang Biotechnology Co.,Ltd. Number: 29-02 Volume: 33 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180724 Address after: 200233 Guiping Road, Xuhui District, Shanghai, room 505, room 418 Patentee after: Shanghai an Zhuo Technology Co.,Ltd. Address before: 200233 Guiping Road, Xuhui District, Shanghai, room 507, room 418 Patentee before: SHANGHAI YIKANG BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181112 Address after: 313008 1/F, No. 1888 Daishan Road, Wuxing District, Huzhou City, Zhejiang Province Patentee after: Huzhou Peptide Biotechnology Co.,Ltd. Address before: 200233 Guiping Road, Xuhui District, Shanghai, room 505, room 418 Patentee before: Shanghai an Zhuo Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230907 Address after: 313000 East of the second floor of the standard plant, No. 5, No. 1888, Daishan Road, Balidian Town, Wuxing District, Huzhou, Zhejiang Province Patentee after: Huzhou Dingxiang Technology Co.,Ltd. Address before: 313008 1/F, No. 1888 Daishan Road, Wuxing District, Huzhou City, Zhejiang Province Patentee before: Huzhou Peptide Biotechnology Co.,Ltd. |